Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Neurocrine Biosciences (NBIX) over the last 14 years, with Q4 2025 value amounting to 0.17%.

  • Neurocrine Biosciences' Return on Capital Employed fell 200.0% to 0.17% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.17%, marking a year-over-year decrease of 200.0%. This contributed to the annual value of 0.18% for FY2025, which is 100.0% down from last year.
  • Per Neurocrine Biosciences' latest filing, its Return on Capital Employed stood at 0.17% for Q4 2025, which was down 200.0% from 0.16% recorded in Q3 2025.
  • Over the past 5 years, Neurocrine Biosciences' Return on Capital Employed peaked at 0.19% during Q3 2024, and registered a low of 0.01% during Q1 2023.
  • Moreover, its 4-year median value for Return on Capital Employed was 0.15% (2025), whereas its average is 0.12%.
  • In the last 5 years, Neurocrine Biosciences' Return on Capital Employed tumbled by -2400bps in 2021 and then skyrocketed by 1600bps in 2024.
  • Neurocrine Biosciences' Return on Capital Employed (Quarter) stood at 0.05% in 2021, then soared by 95bps to 0.1% in 2023, then surged by 75bps to 0.18% in 2024, then fell by -9bps to 0.17% in 2025.
  • Its last three reported values are 0.17% in Q4 2025, 0.16% for Q3 2025, and 0.15% during Q2 2025.